Beverley M Shields

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8993261/publications.pdf

Version: 2024-02-01

93 papers 6,932 citations

43 h-index 79 g-index

96 all docs 96
docs citations

96 times ranked 7767 citing authors

#	Article	IF	CITATIONS
1	Maturity-onset diabetes of the young (MODY): how many cases are we missing?. Diabetologia, 2010, 53, 2504-2508.	2.9	560
2	Maternal and fetal genetic effects on birth weight and their relevance to cardio-metabolic risk factors. Nature Genetics, 2019, 51, 804-814.	9.4	402
3	Frequency and phenotype of type 1 diabetes in the first six decades of life: a cross-sectional, genetically stratified survival analysis from UK Biobank. Lancet Diabetes and Endocrinology,the, 2018, 6, 122-129.	5. 5	291
4	Disease progression and treatment response in data-driven subgroups of type 2 diabetes compared with models based on simple clinical features: an analysis using clinical trial data. Lancet Diabetes and Endocrinology,the, 2019, 7, 442-451.	5.5	280
5	Prevalence of Vascular Complications Among Patients With Glucokinase Mutations and Prolonged, Mild Hyperglycemia. JAMA - Journal of the American Medical Association, 2014, 311, 279.	3.8	257
6	The majority of patients with long-duration type 1 diabetes are insulin microsecretors and have functioning beta cells. Diabetologia, 2014, 57, 187-191.	2.9	240
7	Effective Treatment With Oral Sulfonylureas in Patients With Diabetes Due to Sulfonylurea Receptor 1 (SUR1) Mutations. Diabetes Care, 2008, 31, 204-209.	4.3	239
8	The development and validation of a clinical prediction model to determine the probability of MODY in patients with young-onset diabetes. Diabetologia, 2012, 55, 1265-1272.	2.9	238
9	A Type 1 Diabetes Genetic Risk Score Can Aid Discrimination Between Type 1 and Type 2 Diabetes in Young Adults. Diabetes Care, 2016, 39, 337-344.	4.3	231
10	Association of Thyroid Function Test Abnormalities and Thyroid Autoimmunity With Preterm Birth. JAMA - Journal of the American Medical Association, 2019, 322, 632.	3.8	224
11	Recognition and Management of Individuals With Hyperglycemia Because of a Heterozygous Glucokinase Mutation. Diabetes Care, 2015, 38, 1383-1392.	4.3	217
12	Systematic Population Screening, Using Biomarkers and Genetic Testing, Identifies 2.5% of the U.K. Pediatric Diabetes Population With Monogenic Diabetes. Diabetes Care, 2016, 39, 1879-1888.	4.3	172
13	Cross-sectional and longitudinal studies suggest pharmacological treatment used in patients with glucokinase mutations does not alter glycaemia. Diabetologia, 2014, 57, 54-56.	2.9	164
14	Identification of Novel Genetic Loci Associated with Thyroid Peroxidase Antibodies and Clinical Thyroid Disease. PLoS Genetics, 2014, 10, e1004123.	1.5	150
15	Markers of β-Cell Failure Predict Poor Glycemic Response to GLP-1 Receptor Agonist Therapy in Type 2 Diabetes. Diabetes Care, 2016, 39, 250-257.	4.3	132
16	Urinary C-Peptide Creatinine Ratio Is a Practical Outpatient Tool for Identifying Hepatocyte Nuclear Factor 1-1±/Hepatocyte Nuclear Factor 4-1± Maturity-Onset Diabetes of the Young From Long-Duration Type 1 Diabetes. Diabetes Care, 2011, 34, 286-291.	4.3	123
17	Population-Based Assessment of a Biomarker-Based Screening Pathway to Aid Diagnosis of Monogenic Diabetes in Young-Onset Patients. Diabetes Care, 2017, 40, 1017-1025.	4.3	111
18	Most People With Long-Duration Type 1 Diabetes in a Large Population-Based Study Are Insulin Microsecretors. Diabetes Care, 2015, 38, 323-328.	4.3	104

#	Article	IF	CITATIONS
19	Use of HbA1c in the Identification of Patients with Hyperglycaemia Caused by a Glucokinase Mutation: Observational Case Control Studies. PLoS ONE, 2013, 8, e65326.	1.1	101
20	Type 1 diabetes defined by severe insulin deficiency occurs after 30Âyears of age and is commonly treated as type 2 diabetes. Diabetologia, 2019, 62, 1167-1172.	2.9	100
21	Studies of insulin and proinsulin in pancreas and serum support the existence of aetiopathological endotypes of type 1 diabetes associated with age at diagnosis. Diabetologia, 2020, 63, 1258-1267.	2.9	98
22	Fetal Thyroid Hormone Level at Birth Is Associated with Fetal Growth. Journal of Clinical Endocrinology and Metabolism, 2011, 96, E934-E938.	1.8	97
23	Increased allâ€cause and cardiovascular mortality in monogenic diabetes as a result of mutations in the HNF1A gene. Diabetic Medicine, 2010, 27, 157-161.	1.2	96
24	Sex and BMI Alter the Benefits and Risks of Sulfonylureas and Thiazolidinediones in Type 2 Diabetes: A Framework for Evaluating Stratification Using Routine Clinical and Individual Trial Data. Diabetes Care, 2018, 41, 1844-1853.	4.3	91
25	Can clinical features be used to differentiate type 1 from type 2 diabetes? A systematic review of the literature. BMJ Open, 2015, 5, e009088.	0.8	81
26	C-Peptide Decline in Type 1 Diabetes Has Two Phases: An Initial Exponential Fall and a Subsequent Stable Phase. Diabetes Care, 2018, 41, 1486-1492.	4.3	81
27	Adherence to Oral Glucose-Lowering Therapies and Associations With 1-Year HbA1c: A Retrospective Cohort Analysis in a Large Primary Care Database. Diabetes Care, 2016, 39, 258-263.	4.3	79
28	Evidence of genetic regulation of fetal longitudinal growth. Early Human Development, 2005, 81, 823-831.	0.8	75
29	Lower Circulating B12 Is Associated with Higher Obesity and Insulin Resistance during Pregnancy in a Non-Diabetic White British Population. PLoS ONE, 2015, 10, e0135268.	1.1	74
30	Logistic regression has similar performance to optimised machine learning algorithms in a clinical setting: application to the discrimination between type 1 and type 2 diabetes in young adults. Diagnostic and Prognostic Research, 2020, 4, 6.	0.8	69
31	Measurement of Cord Insulin and Insulin-Related Peptides Suggests That Girls Are More Insulin Resistant Than Boys at Birth. Diabetes Care, 2007, 30, 2661-2666.	4.3	68
32	Precision Medicine in Type 2 Diabetes: Clinical Markers of Insulin Resistance Are Associated With Altered Short- and Long-term Glycemic Response to DPP-4 Inhibitor Therapy. Diabetes Care, 2018, 41, 705-712.	4.3	67
33	The Exeter Family Study of Childhood Health (EFSOCH): study protocol and methodology. Paediatric and Perinatal Epidemiology, 2006, 20, 172-179.	0.8	65
34	A UK nationwide prospective study of treatment change in MODY: genetic subtype and clinical characteristics predict optimal glycaemic control after discontinuing insulin and metformin. Diabetologia, 2018, 61, 2520-2527.	2.9	65
35	Cigarette Smoking during Pregnancy Is Associated with Alterations in Maternal and Fetal Thyroid Function. Journal of Clinical Endocrinology and Metabolism, 2009, 94, 570-574.	1.8	64
36	Time trends in prescribing of type 2 diabetes drugs, glycaemic response and risk factors: A retrospective analysis of primary care data, 2010–2017. Diabetes, Obesity and Metabolism, 2019, 21, 1576-1584.	2.2	64

#	Article	IF	CITATIONS
37	Time trends and geographical variation in prescribing of drugs for diabetes in England from 1998 to 2017. Diabetes, Obesity and Metabolism, 2018, 20, 2159-2168.	2.2	63
38	Urine C-Peptide Creatinine Ratio Is a Noninvasive Alternative to the Mixed-Meal Tolerance Test in Children and Adults With Type 1 Diabetes. Diabetes Care, 2011, 34, 607-609.	4.3	62
39	Lessons From the Mixed-Meal Tolerance Test. Diabetes Care, 2013, 36, 195-201.	4.3	61
40	Stability and Reproducibility of a Single-Sample Urinary C-Peptide/Creatinine Ratio and Its Correlation with 24-h Urinary C-Peptide. Clinical Chemistry, 2009, 55, 2035-2039.	1.5	60
41	Practical Classification Guidelines for Diabetes in patients treated with insulin: a cross-sectional study of the accuracy of diabetes diagnosis. British Journal of General Practice, 2016, 66, e315-e322.	0.7	60
42	Maternal hypothyroxinaemia in pregnancy is associated with obesity and adverse maternal metabolic parameters. European Journal of Endocrinology, 2016, 174, 51-57.	1.9	58
43	Latent Autoimmune Diabetes of Adults (LADA) Is Likely to Represent a Mixed Population of Autoimmune (Type 1) and Nonautoimmune (Type 2) Diabetes. Diabetes Care, 2021, 44, 1243-1251.	4.3	52
44	Random nonâ€fasting C–peptide: bringing robust assessment of endogenous insulin secretion to the clinic. Diabetic Medicine, 2016, 33, 1554-1558.	1.2	50
45	Development and validation of multivariable clinical diagnostic models to identify type 1 diabetes requiring rapid insulin therapy in adults aged 18–50 years. BMJ Open, 2019, 9, e031586.	0.8	49
46	Risk factors for genital infections in people initiating SGLT2 inhibitors and their impact on discontinuation. BMJ Open Diabetes Research and Care, 2020, 8, e001238.	1.2	43
47	Five-Year Follow-Up for Women With Subclinical Hypothyroidism in Pregnancy. Journal of Clinical Endocrinology and Metabolism, 2013, 98, E1941-E1945.	1.8	42
48	EDTA Improves Stability of Whole Blood C-Peptide and Insulin to Over 24 Hours at Room Temperature. PLoS ONE, 2012, 7, e42084.	1.1	39
49	Fetal Genotype and Maternal Glucose Have Independent and Additive Effects on Birth Weight. Diabetes, 2018, 67, 1024-1029.	0.3	38
50	A Type 1 Diabetes Genetic Risk Score Can Identify Patients With GAD65 Autoantibody–Positive Type 2 Diabetes Who Rapidly Progress to Insulin Therapy. Diabetes Care, 2019, 42, 208-214.	4.3	35
51	Urine Câ€peptide creatinine ratio is an alternative to stimulated serum Câ€peptide measurement in lateâ€onset, insulinâ€treated diabetes. Diabetic Medicine, 2011, 28, 1034-1038.	1.2	32
52	Effect of perchlorate and thiocyanate exposure on thyroid function of pregnant women from South-West England: a cohort study. Thyroid Research, 2018, 11, 9.	0.7	32
53	Persistent Câ€peptide is associated with reduced hypoglycaemia but not HbA _{1c} in adults with longstanding Type 1 diabetes: evidence for lack of intensive treatment in UK clinical practice?. Diabetic Medicine, 2019, 36, 1092-1099.	1.2	32
54	Mutations in the Glucokinase Gene of the Fetus Result in Reduced Placental Weight. Diabetes Care, 2008, 31, 753-757.	4.3	30

#	Article	IF	CITATIONS
55	Phosphodiesterase 8B Gene Polymorphism Is Associated with Subclinical Hypothyroidism in Pregnancy. Journal of Clinical Endocrinology and Metabolism, 2009, 94, 4608-4612.	1.8	30
56	Random non-fasting C-peptide testing can identify patients with insulin-treated type 2 diabetes at high risk of hypoglycaemia. Diabetologia, 2018, 61, 66-74.	2.9	30
57	Home urine C-peptide creatinine ratio testing can identify type 2 and MODY in pediatric diabetes. Pediatric Diabetes, 2012, 14, n/a-n/a.	1.2	29
58	lodine deficiency amongst pregnant women in South-West England. Clinical Endocrinology, 2017, 86, 451-455.	1.2	29
59	South Asian individuals with diabetes who are referred for MODY testing in the UK have a lower mutation pick-up rate than white European people. Diabetologia, 2016, 59, 2262-2265.	2.9	28
60	Cohort profile for the MASTERMIND study: using the Clinical Practice Research Datalink (CPRD) to investigate stratification of response to treatment in patients with type 2 diabetes. BMJ Open, 2017, 7, e017989.	0.8	28
61	Prematurity and Genetic Testing for Neonatal Diabetes. Pediatrics, 2016, 138, .	1.0	27
62	Should Studies of Diabetes Treatment Stratification Correct for Baseline HbA1c?. PLoS ONE, 2016, 11, e0152428.	1.1	26
63	Are we missing hypoglycaemia? Elderly patients with insulin-treated diabetes present to primary care frequently with non-specific symptoms associated with hypoglycaemia. Primary Care Diabetes, 2018, 12, 139-146.	0.9	24
64	Assessing newborn body composition using principal components analysis: differences in the determinants of fat and skeletal size. BMC Pediatrics, 2006, 6, 24.	0.7	21
65	Zinc Transporter 8 Autoantibodies (ZnT8A) and a Type 1 Diabetes Genetic Risk Score Can Exclude Individuals With Type 1 Diabetes From Inappropriate Genetic Testing for Monogenic Diabetes. Diabetes Care, 2019, 42, e16-e17.	4.3	19
66	Paternal insulin resistance and its association with umbilical cord insulin concentrations. Diabetologia, 2006, 49, 2668-2674.	2.9	18
67	TriMaster: randomised double-blind crossover study of a DPP4 inhibitor, SGLT2 inhibitor and thiazolidinedione as second-line or third-line therapy in patients with type 2 diabetes who have suboptimal glycaemic control on metformin treatment with or without a sulfonylurea—a MASTERMIND study protocol. BMI Open. 2020. 10. e042784.	0.8	17
68	Improvements in Awareness and Testing Have Led to a Threefold Increase Over 10 Years in the Identification of Monogenic Diabetes in the U.K Diabetes Care, 2022, 45, 642-649.	4. 3	17
69	Histological validation of a type 1 diabetes clinical diagnostic model for classification of diabetes. Diabetic Medicine, 2020, 37, 2160-2168.	1.2	15
70	Evaluating associations between the benefits and risks of drug therapy in type 2 diabetes: a joint modeling approach. Clinical Epidemiology, 2018, Volume 10, 1869-1877.	1.5	14
71	Determinants of insulin concentrations in healthy 1-week-old babies in the community: Applications of a bloodspot assay. Early Human Development, 2006, 82, 143-148.	0.8	12
72	Towards a systematic nationwide screening strategy for MODY. Diabetologia, 2017, 60, 609-612.	2.9	12

#	Article	IF	CITATIONS
73	Identifying Good Responders to Glucose Lowering Therapy in Type 2 Diabetes: Implications for Stratified Medicine. PLoS ONE, 2014, 9, e111235.	1.1	12
74	Exocrine pancreatic dysfunction is common in hepatocyte nuclear factor $1\hat{1}^2$ -associated renal disease and can be symptomatic. CKJ: Clinical Kidney Journal, 2018, 11, 453-458.	1.4	10
75	What to do with diabetes therapies when HbA1c lowering is inadequate: add, switch, or continue? A MASTERMIND study. BMC Medicine, 2019, 17, 79.	2.3	10
76	Identifying routine clinical predictors of nonâ€adherence to secondâ€line therapies in type 2 diabetes: A retrospective cohort analysis in a large primary care database. Diabetes, Obesity and Metabolism, 2020, 22, 59-65.	2.2	10
77	Prior event rate ratio adjustment produced estimates consistent with randomized trial: a diabetes case study. Journal of Clinical Epidemiology, 2020, 122, 78-86.	2.4	10
78	Patterns of postmeal insulin secretion in individuals with sulfonylurea-treated KCNJ11 neonatal diabetes show predominance of non-KATP-channel pathways. BMJ Open Diabetes Research and Care, 2019, 7, e000721.	1.2	9
79	Genetic influences on the association between fetal growth and susceptibility to type 2 diabetes. Journal of Developmental Origins of Health and Disease, 2010, 1, 96-105.	0.7	8
80	Strategies to identify individuals with monogenic diabetes: results of an economic evaluation. BMJ Open, 2020, 10, e034716.	0.8	8
81	Glycated haemoglobin measurements from UK Biobank are different to those in linked primary care records: implications for combining biochemistry data from research studies and routine clinical care. International Journal of Epidemiology, 2022, 51, 1022-1024.	0.9	7
82	Investigating the causal effect of maternal vitamin B12 and folate levels on offspring birthweight. International Journal of Epidemiology, 2021, 50, 179-189.	0.9	6
83	The challenge of diagnosing type 1 diabetes in older adults. Diabetic Medicine, 2020, 37, 1781-1782.	1.2	5
84	Choice of HbA1c threshold for identifying individuals at high risk of type 2 diabetes and implications for diabetes prevention programmes: a cohort study. BMC Medicine, 2021, 19, 184.	2.3	5
85	HbA1c performs well in monitoring glucose control even in populations with high prevalence of medical conditions that may alter its reliability: the OPTIMAL observational multicenter study. BMJ Open Diabetes Research and Care, 2021, 9, e002350.	1.2	5
86	Genetic risk scores in adult-onset type 1 diabetes $\hat{a}\in$ "Authors' reply. Lancet Diabetes and Endocrinology,the, 2018, 6, 169.	5 . 5	4
87	Identifying clinical criteria to predict Type 1 diabetes, as defined by absolute insulin deficiency: a systematic review protocol. BMJ Open, 2012, 2, e002309.	0.8	3
88	Clusters provide a better holistic view of type 2 diabetes than simple clinical features – Authors' reply. Lancet Diabetes and Endocrinology,the, 2019, 7, 669.	5 . 5	3
89	Maternal thyroid function in pregnant women with a breech presentation in late gestation. Clinical Endocrinology, 2016, 85, 320-322.	1.2	2
90	Association of birthweight and penetrance of diabetes in individuals with HNF4A-MODY: a cohort study. Diabetologia, 2022, 65, 246-249.	2.9	2

#	Article	IF	CITATIONS
91	Birth weight and diazoxide unresponsiveness strongly predict the likelihood of congenital hyperinsulinism due to a mutation in ABCC8 or KCNJ11. European Journal of Endocrinology, 2021, 185, 813-818.	1.9	2
92	Continuous glucose monitoring demonstrates low risk of clinically significant hypoglycemia associated with sulphonylurea treatment in an African type 2 diabetes population: results from the OPTIMAL observational multicenter study. BMJ Open Diabetes Research and Care, 2022, 10, e002714.	1.2	2
93	Response to Comment on: Besser et al. Lessons From the Mixed-Meal Tolerance Test: Use of 90-Minute and Fasting C-Peptide in Pediatric Diabetes. Diabetes Care 2013;36:195-201. Diabetes Care, 2013, 36, e222-e222.	4.3	0